Information for Health Professionals: Tindamax (tinidazole)

Think twice, prescribe once with Tindamax^®

An effective therapy that reduces the risks of vaginal candidiasis

The first new oral therapy approved for bacterial vaginosis (BV) in a decade, Tindamax^® protects lactobacilli while targeting BV pathogens—and has a low incidence of secondary vaginal candidiasis (4.7%).

One treatment for bacterial vaginosis (BV) and trichomoniasis (TV)

Studies show that many patients with TV are also positive for BV.^1-5 Tindamax^® is the only medication approved as both an antibacterial agent for BV and antiprotozoal treatment for TV.⁶

Convenient dosing with a favorable side effect profile

Tindamax^® offers a shorter and more convenient treatment for bacterial vaginosis than the current standard of care. A second-generation nitroimidazole, it is well tolerated with a low incidence of GI adverse effects.⁶

Krieger J, Tam M, Stevens C et al. Diagnosis of trichomoniasis, comparison of conventional wet-mount examination with cytologic studies, cultures, and monoclonal antibody staining of direct specimens. JAMA. 1988;259:1223-1227.
Hillier SL, Krohn MA, Nugent RP, Gibbs RS. Characteristics of three vaginal flora patterns assessed by gram stain among pregnant women. Vaginal Infections and Prematurity Study Group. Am J Obstet Gynecol. 1992 Mar;166(3):938-44.
Dan M, Sobel JD. Trichomoniasis as seen in a chronic vaginitis clinic. Infect Dis Obstet Gynecol. 1996;4(2):77-84.
Heine RP, McGregor JA, Patterson E, Draper D, French J, Jones W. Trichomonas vaginalis: Diagnosis and Clinical Characteristics in Pregnancy. Infect Dis Obstet Gynecol. 1994;1(5):228-34.
Demirezen S, Korkmaz E, Beksaç MS. Association between trichomoniasis and bacterial vaginosis: examination of 600 cervicovaginal smears. Cent Eur J Public Health. 2005 Jun;13(2):96-8.
Data on file. Mission Pharmacal Company.